Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd. (NASDAQ:URGN), filed a Form 4 on September 9, 2026, reporting the vesting of restricted stock units and a subsequent sale of ordinary shares on September 7 and 8, 2026.
Key Highlights
- RSU vesting: 1,667 restricted stock units converted to ordinary shares on September 7, 2026, via transaction code M.
- Shares sold: 871 ordinary shares were sold on September 8, 2026, at a price of $42.92 per share.
- Purpose of sale: According to the filing, the shares were sold to satisfy withholding tax obligations upon RSU settlement.
- Remaining ownership: Following both transactions, Schoenberg directly held 59,882 ordinary shares.
- Original RSU grant: The filing states the RSUs were originally granted on September 7, 2023, representing 5,000 ordinary shares, vesting in three equal annual installments from September 7, 2024.
- Derivative position: The RSU balance reported in Table II following the transaction is 0, reflecting full settlement of this tranche.
UroGen Pharma CMO RSU Settlement Details and Share Position
According to the Form 4 filing, Mark Schoenberg, identified as Chief Medical Officer of UroGen Pharma Ltd., reported two transactions in the company's ordinary shares across consecutive days. On September 7, 2026, 1,667 restricted stock units settled into ordinary shares under transaction code M. The filing notes that each RSU represents a contingent right to receive one ordinary share of the issuer, and the conversion or exercise price of the derivative security is listed as $0.
The following day, September 8, 2026, the filing reports that 871 ordinary shares were disposed of at $42.92 per share. The filing's explanation of responses states that these shares were "sold to satisfy withholding tax obligations upon the settlement of restricted stock units." This type of disposition is commonly reported in connection with RSU vesting events where a portion of shares is withheld or sold to cover tax liabilities, as described by the registrant.
The filing further discloses that the RSUs settled in this transaction originated from a grant made on September 7, 2023, for 5,000 ordinary shares in total, with vesting scheduled "in three equal annual installments from September 7, 2024." Following all reported transactions, Schoenberg's direct beneficial ownership stood at 59,882 ordinary shares, with no remaining derivative securities from this particular RSU grant reported in Table II.
What Was Disclosed
UroGen Pharma's Chief Medical Officer disclosed the vesting of 1,667 RSUs and the sale of 871 ordinary shares at $42.92 to cover tax obligations, leaving a direct holding of 59,882 ordinary shares as of September 8, 2026.






Please wait processing your request...